|
注册号: Registration number: |
ChiCTR2100053422 |
|
最近更新日期: Date of Last Refreshed on: |
2022-09-27 04:37:54 |
|
注册时间: Date of Registration: |
2021-11-20 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
艾司氯胺酮在预防剖宫产患者产后抑郁中的作用 |
|
Public title: |
Effects of esketamine on the prevention of postpartum depression in cesarean section patients |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
艾司氯胺酮在预防剖宫产患者产后抑郁中的作用 |
|
Scientific title: |
Effects of esketamine on the prevention of postpartum depression in cesarean section patients |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
徐世霞 |
研究负责人: |
徐世霞 |
|
Applicant: |
Xu Shixi |
Study leader: |
Xu Shixi |
|
申请注册联系人电话: Applicant telephone: |
+86 15261873964 |
研究负责人电话:
Study leader's |
+86 15261873964 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
xsx1987112@126.com |
研究负责人电子邮件: Study leader's E-mail: |
xsx1987112@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江苏南京市鼓楼区丁家桥87号 |
研究负责人通讯地址: |
江苏南京市鼓楼区丁家桥87号 |
|
Applicant address: |
87 Dingjiaqiao, Gulou District, Nanjing, Jiangsu |
Study leader's address: |
87 Dingjiaqiao, Gulou District, Nanjing, Jiangsu |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
东南大学附属中大医院 |
||
|
Applicant's institution: |
Zhongda Hospital affiliated to Southeast University |
||
|
研究负责人所在单位: |
东南大学附属中大医院 |
||
|
Affiliation of the Leader: |
Zhongda Hospital affiliated to Southeast University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2020ZDSYLL265-P01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
东南大学附属中大医院临床研究伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Zhongda Hospital affiliated to Southeast University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2021-01-08 00:00:00 | ||
|
伦理委员会联系人: |
王慧萍 |
||
|
Contact Name of the ethic committee: |
Wang Huiping |
||
|
伦理委员会联系地址: |
江苏南京市鼓楼区丁家桥87号 |
||
|
Contact Address of the ethic committee: |
87 Dingjiaqiao, Gulou District, Nanjing, Jiangsu |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
东南大学附属中大医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Zhongda Hospital affiliated to Southeast University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江苏南京市鼓楼区丁家桥87号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
87 Dingjiaqiao, Gulou District, Nanjing, Jiangsu |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
self-raised |
||||||||||||||||||||||
|
研究疾病: |
产后抑郁 |
||||||||||||||||||||||
|
Target disease: |
Postpartum depression |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本研究想通过剖宫产术中给予静脉泵注亚麻醉剂量的盐酸艾司氯胺酮(0.2 mg/kg),观察产妇术后抑郁的发生率,从而探讨盐酸艾司氯胺酮能否预防产后抑郁的发生,通过比较抑郁组和非抑郁组产妇的静脉血中的指标的改变,探讨产后抑郁发生的可能机制。 |
||||||||||||||||||||||
|
Objectives of Study: |
This research wants to give intravenous injection pump and anesthesia in cesarean section of escitalopram ketamine hydrochloride (0.2 mg/kg), to observe the incidence of depression after ChanFuShu, which discuss escitalopram ketamine hydrochloride can prevent the occurrence of postpartum depression, through comparing the depression and the depression group of maternal venous blood indicators of change, to explore the possible mechanism of postpartum depression. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.未禁食禁饮; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Not fasting and fasting; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-11-15 00:00:00至 To 2023-11-15 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2021-11-15 00:00:00 至 To 2023-11-15 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
采用电脑随机数字表法进行随机分组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Randomized groups were assigned and studied using a computerized random number table. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
在剖腹产当天,对研究方案不知情的助理按受试者登记顺序打开信封,将研究药物重新放入20ml注射器中,然后在注射器上贴上受试者签名的ID。受试者、麻醉师和随访调查人员都不知道受试者的分组情况。 |
|
Blinding: |
Blind method for subjects, anesthesiologists and follow-up investigators. |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
发表文章后公开 请说明共享原始数据的方式 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
I will make it public after the article published |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |